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Now..... 
What Do I Do With All This Paper 
Michelle Jenkerson 
Research Participant Advocate 
Washington University School of 
Medicine 
Now We Know.... 
• How to write a protocol – Dr. 
Kharasch 
• Grant vs. Protocol – Dr. 
Coopersmith 
• Protocol Issues – Sarah 
Fowler-Dixon 
• Now we need what to do 
with all this......... 
Objectives 
• Familiar with research data to capture 
 
• Essential regulations 
 
• Organizing research records 
– Regulatory binder 
– Participant research records 
 
• Understanding what “research data” is 
 
• Knowing what a source document is 
 
Read & Re-Read 
• Become familiar with the 
protocol 
– Take notes 
– Highlight 
– Place sticky notes 
– Look at logistics 
• Now that you are familiar 
we can proceed 
Consider Writing Standard 
Operating Procedures (SOPs) 
• Purpose: 
– Ensure consistent processes 
– Meet or exceed regulatory & 
GCP standards 
 
• Ensure processes are 




SOPs – Not Required by Regulations 
• 21CFR 312.53: 
– “The PI will ensure that all staff are 
informed about their obligations.” 
 
• SOPs:  
– Better prepares study team 
 
– Processes will be consistent 
 
– Appear more professional 
 
– FYI: Industry are now asking to review 
SOPs 
SOPs 
• Writing SOPs  
 
– Not easy task 
 
– Time consuming 
 




SOPs vs. Guidelines 
• SOP: 
– Gives a birds eye view of 
process 
– Include all the main steps 
• Guidelines: 
– More detailed 
– Allow someone to complete 
the process by following 
steps in guideline 
 
SOPs vs. Guidelines 
• SOPs: 
– Approved at higher administrative  
level 
– Not changed on a whim 
– Rarely need to be changed 
• Guidelines: 
– May change more frequently 
• Changes: 
– Organizational structure 
– Equipment 
– Personnel functions 
• Formulated or updated at 
departmental level 
 
SOPs vs. Guidelines 
 
• More than 1 guideline 
attached to an SOP 
 
 
• Some SOPs may not need 
guidelines 
SOPs vs. Guidelines 










– List tasks to complete process 
– List person or function responsible for 
completing each task 
– Much more detailed 
• May need to be changed, even if SOP 
remains valid & appropriate 
SOP & Guideline Approval Process 
• SOPs 
– Subject to review by any 
groups or departments that 
are affected by them 
 
– Review helps ensure that 




– Review annually or every 2 years 
• Ensure they are still workable 
• Ensure they are being followed 
– Changes: 
• SOPs should be revised to reflect 
change 
• Amend guidelines 
– Assign someone to maintain 
SOPs/Guidelines: 
• Current 
• History of documents & revisions 
• Maintain all previous versions – 
include dates during which SOP 
was in effect 
• Provides an audit trail for process 
changes 
Approved SOPs & Guidelines 
• Critical: 
– Train personnel involved 
– Only functional if people know 
what they are & follow them 
• Approved: 
– Train staff 
– Implement 
– Note: approval date usually 
precedes the implementation 
date 
– Employees should have access 
• Online 
• Hard copies 
What Do We Do With All These Study 
Related Papers?? 
 











• Documentation of research data is not 
optional.....it is a must! 
 
• Complete record keeping = valid data 
integrity......it is a must! 
 
• Keeping essential “research information” 
is the law.......it is a must! 
 
• Complete & proper documentation & 
record keeping is an “ethical” 
practice.....it is a must! 
 
• Incomplete data & record keeping: 




Who Is the “Sponsor” 
• Note: 
– In Investigator-initiated studies, the 
PI as the Investigator may hold the 
IND and also have all the sponsor 
responsibilities 
 
– The sponsor of a study (to whom 
the IND is issued) has extensive 
obligation under 21 CFR 314 (e.g. 
study monitoring, adverse event 
and other reporting to the FDA) 
Creating Files- Regulatory Binder 
• Protocol  
• Grant & updates 
• IB, if applicable 
• 1572, if applicable 
• 1571, if PI is IND Sponsor 
• CVs of PI and Sub-Is 
• Licenses 
• Training Certificates,  
– HIPAA 
– CITI 
– Signature Logs 
• Other Credentials, if appropriate 
• Clinical Investigator Financial Disclosure 
Forms 
• Drug Data Sheets 
• Letter HRPO membership & Assurance # 
• SOPs – for this protocol 




Creating Files- Regulatory Binder, 
Continued 
• HRPO Correspondence 
– Initial Approval 
– Consent forms 
– Amendments 
– AE/SAE reports 
– Advertisement 
– Continuing Renewals 
• DSMB Reports 
• Normal lab values & tests that will be used 
• CLIA/CAP certification for lab – if required 
• Delegation of Authority Log/Staff signature log & initial log 
• Sponsor Correspondence, if applicable 
• FDA Correspondence, if applicable 
• Study Agreements 
• Contracts 
– Disclosure Agreements 
– Other sites, if applicable 
• Samples 
– Data collection forms –Source Docs 
– CRFs 
• As study proceeds, may need to file external adverse 
event reports and IND safety reports 
An Old Nursing Adage: 
 
 
Repeat after me: 
 
”If it’s not documented,  
it wasn’t done.” 
 
 
Definition: Participant Research 
Record/Chart 
• Often, a separate research 
record maintained in 
addition to the patient 
medical record, - research 
purposes 
PI Responsibility 
• FDA 21 CFR 312.62 (b) 
• Investigator record keeping & 
record retention: 
– “Case histories: An investigator is 
required to prepare and maintain 
adequate and accurate case 
histories that record all 
observations and other data 
pertinent to the investigation on 
each individual administered the 
investigational drug or employed 
as a control in the investigation.” 
21 CFR 312.62(b)Continued: 
• “Case histories include the case 
report forms and supporting 
data including, for example, 
progress notes of the physician, 
the individuals hospital chart(s) 
and the nurses’ notes. The case 
history for each individual shall 
document that IC was 
obtained prior to participation 
in the study.” 
 
Participant Research Record 
• Consider how: 
– Organize record/chart 
 
–  Participant’s will be identified: 
 
• Unique identifier –Master List 
 
• Number – Master List 
 
• Initials plus number – Master List 
 
• By Name 
 
Also Prepare 
• Maintain a screening log: 
– Date screened 
– Date randomized 
– If kept on computer   
• password protect 
 
• Maintain enrollment Log 
– Date of enrollment 
– If kept on computer   
• password protect 
Contents of Participant Research 
Record 
• Signed & dated IC 
– Original – no copy 
• Short narrative: 
– Consent process 
– Copy of IC given to participant 
(ICH E6 4.8.11) 
• “A copy of the ICD must be 
provided to the subject & the 
original signed ICD should be 
retained in the study records” 
Note, FDA regulations do not 
require the subject’s copy to be a 
signed copy, although a 
photocopy with signatures is 
preferred. (FDA Information Sheet 
1998 Update) 
File Supporting Documents In 
Participant Research Record/Chart 
• I/E criteria reviewed 
 
– Met inclusion 
– Met no exclusion 
 
• Check-off list 
• PI review – sign & date 
 
Creating Participant Research 
Record/Chart 
• Set up per visit schedule 
• Forms 
– Actual research data that supports 
the data recorded or measured 
– (Can only collect data per 
protocol) 
• Know data to collect for each 
visit 
• Need to validate data: 
– Comes from source docs 
– Source docs must be available to 
review 
• Organize & file....asap 
 
Source Docs Can Be: 
• Original docs 






• Lab notes 
• Memoranda 
• Diaries 
• Evaluation checklist 
• Pharmacy dispensing records 
• Recorded data from automated instruments 
• Copies or transcriptions certified after verification as 
being accurate copies 
• Microfiches 
• Photographic negatives 
• Microfilm or magnetic media 
• X-rays 
• Participant files 
• Pharmacy records 
 
Incomplete data & record keeping: 
 
• Missing or incomplete data 
– ? Data integrity 
– IRB may inform the PI that 
“data” may not be used 
– ? Participant at risk of harm 
– What is supporting findings 
Creating & Documenting on “Case 
Report Forms (CRFs)” 
• CRFs: 
 
– Used to collect & record 
study data 
 
– CRFs = SD: unless specified in 
study protocol 
 
– Need a supporting SD to 
assure data is valid 
 
Creation of CRFs 
 
• PI: 
– Review CRFs 
– Sign & date 
– This works if there is a 
scheduled time to meet with 
PI.....weekly.....monthly.... 
CRFs 
• Do not: 
 
– Copy CRFs 
 
– Use them as flow sheets 
 




• May want to create & pilot 
forms prior to 
implementation of study 
• Record data on CRFs from 
source documents 
– Record data in real-time 
• Can only collect data that 
has been approved by 
HRPO  
 
Source Document Templates 
• http://research.wustl.edu/Page
s/default.aspx 
– Compliance areas 
– HSR QA/QI 
– Clinical Research Forms 
• View forms 
Participant Research Record 
• All communication 
– Log 
• Method 
– Phone call 
– Email – need approval 
• Schedule: 
– Research procedures  
• Visits 
• Follow up calls 
• Lab, pathology, x-ray, other 
reports 
• Record of study med dispensed 
or device 
Participant Research Record 
• Copies of report sent to 




– Protocol exemptions 
 





– 21 CFR 56.102 (l) 
– Any drug for human use, 
biological product for 
human use, medical device 
for human use, human food 
additive, color additive, 
electronic product, or any 
other article subject to 
regulation under the Public 
Health Service Act 
Study is Using a Test Article? 
• Accountability 
– 21 CFR 312.62 (a) 
• A PI is required to maintain 
adequate records of the 
disposition of the drug, 
including dates, quantity, and 
use by participants 
• Account for: 
– Used products 
– Unused products 
– Returned products 
– Disposal – per protocol or 
sponsor 
Accountability of Study Med 
• Where is the drug coming 
from? 
– Shipping & receiving invoices 
• Type 
• Quantity 
• Date of shipment 
 
• Will the pharmacy be involved? 
– Are they accounting for the drug? 
– Who is dispensing the drug? 
– Who is administering the drug? 
 
• Defined in protocol? 
Required Storage of Study 
Med/Device 
• Med Storage: 
– Temp logs 




– Who is responsible 
– Receipt  
– Count 






• Document on log: 
– Type 
– Quantity 
– Date of shipment 
– Expiration dates 
• Dispensing log: 
– Study personnel dispensed 
• Name on Delegation of Authority Log 
– Quantity to participant 
– Waste 
– Return 
– Batch number/lot number 
– If any product wasted –done per 
policy 
 
Participant Research Record 
• Narrative note in participant 
research record: 
 
– Study med was dispensed to 
participant after participant 
signed the IC.  
 
– Dispensed per protocol. 
 
– Study med information given to 
participant 
Mental Notes 
• Keep test articles in locked storage 
– Access only by authorized study 
personnel 
• Know the count and amount 
• Document immediately: 
– Dispensing 
– Shipping, if applicable 
• Inventory shipments upon arrival 





You Are Organized – You Are Collecting 
Data: 
 
Oops you made a mistake 
documenting..... 
• The “do not’s” 
 
– White out 
 
– Multiple lines scratched through 
 
– Sign or date for anyone else 
 
The “Write” Way to Make Correction 
• 1 line through incorrectly written 
data 
 
• Write corrected data point: 
– Next to incorrect  
– On top of 
 
• Once Corrected: 
– Initial, date correction 
 
• Make sure incorrect & 
corrected value can be seen 
Study Files 
• Document in “real time” 
 
• Review documents for 
accuracy.....make it a 
practice 
 
• Review documents 
regularly during the trial 
In Real Time 
• Periodically review staff 
documentation 
 
• Identify, address & resolve 
document issues asap 
 
• End of study: 
– Inventory & archive documents  
• How long 
– Complete & submit appropriate 
study closure documents to HRPO 
(electronic) 
In Closing 
• Know your studies 
– Read & re-read 
 
• Manage your files 
 
• Routinely review data & SD 
 
• Keep on top of the tasks 
 
• Ask for help 
 
Review/Audits – Internal/External 
• Most important step: 
– Do things correctly from the start 
– Organized files 
• Informed of review/audit: 
– Amass study docs 
– Review study docs prior to review by 
review/audit team 
• IC 
• Participant research records (sampling) 
• CRF 
• Regulatory file 
• Other 
 
• Only provide requested information 
requested by reviewers 
 
Review/Audit  
• Conduct of study: 
 
– Who did what 
– Degree of delegation of 
authority 
– Where specific aspects of study 
were performed 
– How & where data were 
recorded 
– How test article accountability 
was maintained, if applicable 
 
Review/Audit 
• Will review: 
– Diagnosis 
 
– Whether participants were properly 
diagnosed 
 
– Participant met inclusion criteria and 
no exclusion 
 
– Concomitant meds – allowed: not 
allowed 
 
– Follow up of AEs, if applicable 
Review/Audit 
• Reviewers will document 
findings 
 
• Review findings 
 
• Make corrections 





21 CFR 50, 54, 56, 312, 214, 812, 
814 
Common Rule: 
45 CFR 46 
Regulations: 
•45 CFR 46 
•21 CFR – FDA 
NIH Guidelines 
ICH GCP 
HRPO Policies 
Institutional Policies 
